Navigation Links
Vermillion Sets Third Quarter 2013 Conference Call for Thursday, November 14, 2013
Date:10/31/2013

AUSTIN, Texas, Oct. 31, 2013 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a multivariate diagnostics company focused on gynecologic cancers and women's health, will hold a conference call on Thursday, November 14, 2013, at 4:30 p.m. Eastern time to discuss results for the third quarter ended September 30, 2013. Financial results will be issued in a press release prior to the call.

Vermillion's President and CEO Thomas McLain will host the call, followed by a question and answer period.

Date: Thursday, November 14, 2013
Time: 4:30 p.m. Eastern time (3:30 p.m. Central time)
Dial-in number: 1-800-734-8507
International dial-in number: 1-212- 231-2918
Conference ID: 21676489       
Webcast: http://www.media-server.com/m/p/kb996t2n

The conference call will be webcast live and available for replay via the investor section of the company's website at www.vermillion.com.

Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Liolios Group at 1-949-574-3860.

A replay of the call will be available approximately two hours after the call through November 28, 2013.

Toll-free replay number: 1-800-633-8284
International replay number: 1-402-977-9140
Replay ID: 21676489

About Vermillion
Vermillion, Inc. (NASDAQ: VRML) is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Vermillion Sets First Quarter 2012 Conference Call for Tuesday, May 15, 2012 at 4:30 p.m. ET
2. Vermillion Announces CEO Succession Plan
3. Vermillion PAD Intended Use Study Presented at Society for Vascular Medicine 23rd Annual Scientific Sessions
4. Vermillion Announces Positive Top-Line Results from the OVA500 Multi-Center Study Led by UC Irvine
5. Vermillion Reports Second Quarter 2012 Results
6. Vermillion to Present at the 2012 Gateway Conference on September 6
7. Vermillion Sets Third Quarter 2012 Conference Call for Monday, November 12, 2012 at 4:30 p.m. ET
8. Vermillion Reports Third Quarter 2012 Results
9. Delaware Court of Chancery Dismisses Vermillion Dissident Shareholder Suit with Prejudice
10. Vermillion Appoints Bruce A. Huebner as Interim Chief Executive Officer
11. Gynecologic Oncology Publishes New Clinical Study Showing Positive Performance of OVA1, Vermillions Ovarian Cancer Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/17/2014)...  Inovio Pharmaceuticals, Inc. (NASDAQ: INO ) ... 2013 collaboration, option, and license agreement to co-develop INO-5150, ... their research collaboration in prostate cancer. All of Roche,s ... product to other parties, will be returned to Inovio.  ... I clinical trial in the first half of 2015. ...
(Date:11/16/2014)...  Hanger, Inc. (NYSE: HGR ) announced ... third quarter 2014 financial results and is cancelling its ... for the completion and review of its third quarter ... financial results and reschedule its conference call after the ... About Hanger, Inc. – Built on the ...
(Date:11/16/2014)... 2014 Die führenden ... Zugang zur medizinischen Versorgung in Entwicklungsländern durch ... Innovationen in den letzten beiden Jahren zu ... einigen wesentlichen Bereichen schwer damit, gute Ergebnisse ... "2014 Access to Medicine Index". ...
Breaking Medicine Technology:Inovio Pharmaceuticals to Independently Develop Prostate Cancer Immunotherapy; Will Maintain Collaboration and License Agreement with Roche for Inovio's Hepatitis B Immunotherapy 2Inovio Pharmaceuticals to Independently Develop Prostate Cancer Immunotherapy; Will Maintain Collaboration and License Agreement with Roche for Inovio's Hepatitis B Immunotherapy 3Inovio Pharmaceuticals to Independently Develop Prostate Cancer Immunotherapy; Will Maintain Collaboration and License Agreement with Roche for Inovio's Hepatitis B Immunotherapy 4Inovio Pharmaceuticals to Independently Develop Prostate Cancer Immunotherapy; Will Maintain Collaboration and License Agreement with Roche for Inovio's Hepatitis B Immunotherapy 5Pharmaindustrie unternimmt mehr zur Verbesserung des Zugangs zur medizinischen Versorgung in Entwicklungsländern. Leistungen hinken in manchen Bereichen hinterher 2Pharmaindustrie unternimmt mehr zur Verbesserung des Zugangs zur medizinischen Versorgung in Entwicklungsländern. Leistungen hinken in manchen Bereichen hinterher 3Pharmaindustrie unternimmt mehr zur Verbesserung des Zugangs zur medizinischen Versorgung in Entwicklungsländern. Leistungen hinken in manchen Bereichen hinterher 4Pharmaindustrie unternimmt mehr zur Verbesserung des Zugangs zur medizinischen Versorgung in Entwicklungsländern. Leistungen hinken in manchen Bereichen hinterher 5
... 15, 2012  National data center hosting ... and healthcare technology consulting firm, Burwood Group Inc., ... presentation at the 2012 Annual HIMSS Conference & ... and the importance of disaster recovery planning ...
... 2012 Anlit Advanced Nutrition Supplements , ... supplements for children, will start selling its products ... Anlit will distribute its wide variety of supplements for ... leading local producer of natural healing products. Laboratoria Natury was ...
Cached Medicine Technology:National Data Center Hosting Provider, CoreLink Data Centers, to Present at HIMSS 2012 2National Data Center Hosting Provider, CoreLink Data Centers, to Present at HIMSS 2012 3National Data Center Hosting Provider, CoreLink Data Centers, to Present at HIMSS 2012 4Anlit Enters Polish Market with New Food Supplements for Kids 2
(Date:11/18/2014)... (PRWEB) November 18, 2014 Hawthorne cosmetic ... affordable for patients. Nearly 70 percent of Americans over the ... the age of 74, 25 percent are missing not just ... options are available, but only one offers a look, feel, ... , This special includes a complimentary consultation that allows patients ...
(Date:11/18/2014)... Dennis Thompson HealthDay Reporter ... Driving "bad" LDL cholesterol down to extremely low levels ... attacks and strokes in high-risk patients with clogged arteries, ... attacks and strokes when taking Vytorin, a drug that ... medication called ezetimibe, said principal investigator Dr. Christopher Cannon, ...
(Date:11/18/2014)... By Dennis Thompson ... (HealthDay News) -- An experimental antibody drug could prove ... who have side effects with cholesterol-lowering statin medications. ... at the American Heart Association annual meeting in Chicago. ... is currently the most widely used alternative to statins, ...
(Date:11/18/2014)... TUESDAY, Nov. 18, 2014 (HealthDay News) -- Cocaine users ... is hard to detect, which can put them at ... study warns. Researchers in Chicago compared heart imaging ... who didn,t use the illegal drug. Those using ... heart,s smallest blood vessels, which were considered significant when ...
(Date:11/18/2014)... November 18, 2014 Recently, BellasDress has announced ... Made by qualified workers and using comfortable fabrics, the new ... is carrying a variety of wonderful holiday gifts in a ... welcome these new prom dresses, and they are created by ... collection is an absolutely great addition to our sales team ...
Breaking Medicine News(10 mins):Health News:Hawthorne Dentist, Dr. Yashari, is Now Making Dental Implants More Affordable for Patients 2Health News:Cholesterol Drug Vytorin Linked to Reduced Heart Attack Risk 2Health News:Cholesterol Drug Vytorin Linked to Reduced Heart Attack Risk 3Health News:Experimental Cholesterol-Lowering Drug Effective, Study Reports 2Health News:Experimental Cholesterol-Lowering Drug Effective, Study Reports 3Health News:Cocaine Can Cause Heart Problems: Study 2Health News:85 New Models Of White Prom Dresses From BellasDress.com Online For Sale 2
... Previous studies have shown inhaled corticosteroids can decrease ... say long-term use of ICS therapy is not ... ,Corticosteroids are commonly used to treat asthmatics and ... these medications are good at reducing inflammation and ...
... are creating a whole new experience for patients in ... putting more smiles on their patients' faces.// ,Laser ... tissue removal, less bleeding and less discomfort for patients. ... Some diagnose cavities, while others remove gum and tooth ...
... of rickets as a disease of the past. New ... and prevention should start before birth and researchers suggest ... ,Rickets is a childhood disorder involving softening and weakening ... D, calcium, or phosphate. It is most likely to ...
... new and simple test could be a major improvement for ... to assess a patient's response to HIV medication.// ,HIV ... now becoming available in Africa. While on the medication, tests ... CD4 cell count indicates a need for more intensive treatment ...
... breast cancer patients who receive radiation therapy after ... more likely to develop complications.// However, a new ... ,Researchers from the Fox Chase Cancer Center ... a mastectomy, breast reconstruction, and postoperative radiation between ...
... combination treatment looks like a better option for some ... the size of the tumor //before using lasers to ... the combination treatment improves the overall survival of the ... (LITT) to heat tumors. The problem is the tumor ...
Cached Medicine News:Health News:New Liver Tumor Treatment 2
... Addressing the key clinical and economic issues ... System is designed to maximize tension control ... The system combines efficient instrumentation with a ... Grip system is indicated for general orthopaedic ...
... worlds first multi-filament orthopaedic cable, Dall-Miles™, ... a means of providing superior fixation ... procedures. Today, with more than 100 ... the Dall-Miles™ Cable System continues to ...
The Assistant Free Self-Retaining Hip Surgery Retractor System is used for hip arthroplasty and hip fracture surgery....
... have become the accepted standard for,excellence and ... AML Total Hip System was the first ... meet the needs for biological fixation in ... 15 years of documented clinical performance, the ...
Medicine Products: